These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7909585)

  • 1. Central administration of Tyr-MIF-1 stimulates gastrointestinal motility in rats: evidence for the involvement of dopamine, sigma and CCK receptors.
    Million M; Fioramonti J; Bueno L
    Neuropeptides; 1994 Feb; 26(2):77-85. PubMed ID: 7909585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of Tyr-MIF-1 stimulates gastric emptying and gastrointestinal motility in rodents.
    Million M; Fioramonti J; Bueno L
    Peptides; 1992; 13(3):469-74. PubMed ID: 1355905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptor antagonists block the effect of Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) on the opiate form of footshock-induced analgesia.
    Krowicki ZK
    Neuropeptides; 1991 Aug; 19(4):281-5. PubMed ID: 1681456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat.
    Gué M; Gleïzes-Escala C; Del Rio-Lacheze C; Junien JL; Buéno L
    Br J Pharmacol; 1994 Mar; 111(3):930-4. PubMed ID: 7912631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
    Kostrzewa RM; Kastin AJ
    Brain Res Bull; 1993; 31(6):707-12. PubMed ID: 8100182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats.
    Pulvirenti L; Kastin AJ
    Eur J Pharmacol; 1988 Jul; 151(2):289-92. PubMed ID: 2901971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation.
    Katschinski M; Schirra J; Begliner C; Langbein S; Wank U; D'Amato M; Arnold R
    Eur J Clin Invest; 1996 Jul; 26(7):574-83. PubMed ID: 8864420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural specificity of MIF-1 and Tyr-MIF-1 in augmenting GABA-stimulated benzodiazepine receptor binding.
    Miller LG; Kastin AJ; Roy RB; Gaver A; Fischman AJ; Horvath A
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):365-8. PubMed ID: 2908009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
    Hara C; Kastin AJ
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1785-7. PubMed ID: 2874569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances in rats through sigma and cholecystokinin receptors.
    Gue M; Junien JL; Del Rio C; Bueno L
    J Pharmacol Exp Ther; 1992 Jun; 261(3):850-5. PubMed ID: 1318376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonazepam-induced intestinal motor disturbances are linked to central nervous system release of cholecystokinin in rats.
    Bonnafous C; Martinez J; Fargeas MJ; Buéno L
    Eur J Pharmacol; 1993 Jun; 237(2-3):237-42. PubMed ID: 8396038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of postprandial intestinal motility and release of cholecystokinin by polyamines in rats.
    Fioramonti J; Fargeas MJ; Bertrand V; Pradayrol L; Buéno L
    Am J Physiol; 1994 Dec; 267(6 Pt 1):G960-5. PubMed ID: 7810663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
    Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
    Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of Tyr-MIF-1, MIF-1, and naloxone on peptide YY-induced hyperphagia.
    Hagan MM; Moss DE
    Peptides; 1994; 15(2):243-5. PubMed ID: 7911993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide.
    Mycroft FJ; Bhargava HN; Wei ET
    Peptides; 1987; 8(6):1051-5. PubMed ID: 2894644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of analogs of the endogenous brain peptides Tyr-MIF-1 and Tyr-W-MIF-1.
    Erchegyi J; Zadina JE; Qiu XD; Kersh DC; Ge LJ; Brown MM; Kastin AJ
    Pept Res; 1993; 6(1):31-8. PubMed ID: 8094991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIF-1 and Tyr-MIF-1 augment muscimol-stimulated chloride uptake in cerebral cortex.
    Miller LG; Kastin AJ; Roy RB
    Brain Res Bull; 1989 Dec; 23(6):413-5. PubMed ID: 2575438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
    Gergen KA; Zadina JE; Kastin AJ; Paul D
    Eur J Pharmacol; 1996 Mar; 298(3):235-9. PubMed ID: 8846821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist.
    Gergen KA; Zadina JE; Paul D
    Eur J Pharmacol; 1996 Nov; 316(1):33-8. PubMed ID: 8982647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of a novel tetrapeptide with opiate and antiopiate activity from human brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1).
    Erchegyi J; Kastin AJ; Zadina JE
    Peptides; 1992; 13(4):623-31. PubMed ID: 1359507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.